Hydrolyzed chicken extract (ProBeptigen®) on sleep quality in healthy individuals: a secondary analysis of PSQI global and component scores from a randomized double-blind trial

Background/objectivesPoor sleep is a prevalent health issue. This secondary analysis examined the effects of hydrolyzed chicken extract (ProBeptigen®) on sleep quality outcomes using data from a previously completed single-center, randomized, parallel, double-blind, placebo-controlled trial.MethodsFifty-two healthy subjects with poor baseline sleep quality (Pittsburg Sleep Quality Index, PSQI global > 5) had been randomly assigned to receive either ProBeptigen® 670 mg (n = 24) or a placebo (n = 28) daily. Changes in PSQI total (global) score and individual component scores were analyzed.ResultsFollowing 4 weeks of treatment, changes in PSQI global scores did not significantly differ between the two groups. However, the improvement in the subjective sleep quality component score was significantly greater in the ProBeptigen® group compared to the placebo group (p = 0.006). Additionally, subjects taking ProBeptigen® exhibited a numerically greater improvement in daytime function (p = 0.064).ConclusionThis proof-of-concept secondary analysis suggests that ProBeptigen® may improve perceived sleep quality and support further prospective evaluation.